Cohance Lifesciences Ltd. NSE: COHANCE | BSE: 543064

Cohance Lifesciences Live Share Price Today, Share Analysis and Chart

Name: Cohance Lifesciences Ltd.: Is Infosys Ltd. worth buying?
Item: Cohance Lifesciences Ltd.
Rating: 1.80600
Author: Trendlyne DVM scores

Expensive Underperformer

about

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

310.00 -4.10 (-1.31%)

New 52W Low in past week

763.8K

NSE+BSE Volume

High vol. this week

NSE 24 Feb, 2026 3:13 PM (IST)

Block Deal

Jasti Family Trust sells 77 lakh shares in Cohance Lifesciences worth Rs 236 crore via a block deal See details

Loading... You have run out of DVM views!

Subscribe now to see details

Medium Financial Strength

- / 100

Expensive Valuation

- / 100

Technically Bearish

25.0 / 100

Expensive Underperformer These stocks have average quality, expensive valuations and weak momentum. Investors should exercise caution View Similar Embed DVM

513

1Yr Price target upside is 65%

9 analysts

Cohance Lifesciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

46 Votes:

Buy 71.74%

Sell 17.39%

Hold 10.87%

Cohance Lifesciences Live Share Price Today, Share Analysis and Chart

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

New 52W Low in past week

High vol. this week

SWOT Analysis

Cohance Lifesciences Live Price Chart